Due to this connection, dupilumab, an anti-IL4Rα mAb approved for asthma treatment, and tezepelumab an anti-TSLP mAb also approved for asthma treatment are also being tested in COPD patients with eosinophilia via randomised clinical trials (76–78). Here, IL4R is linked to asthma.